Endoscopic molecular imaging of human bladder cancer using a CD47 antibody

Science Translational Medicine

Volumn 6, Issue 260, 2014, Pages

  Pan, Ying ^a,b   Volkmer, Jens Peter ^c   Mach, Kathleen E ^a,b   Rouse, Robert V ^b,c   Liu, Jen Jane ^a   Sahoo, Debashis ^c   Chang, Timothy C ^a   Metzner, Thomas J ^a   Kang, Lei ^a,b   Van De Rijn, Matt ^c   Skinner, Eila C ^a   Gambhir, Sanjiv S ^d   Weissman, Irving L ^c   Liao, Joseph C ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIBODY; CD47 PROTEIN; DIAGNOSTIC AGENT; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG; CD47 ANTIGEN;

ANTIBODY LABELING; ARTICLE; CANCER GRADING; CD47 GENE; CLINICAL EVALUATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IMAGING; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MARKER GENE; MOLECULAR IMAGING; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; ENDOSCOPY; GENETICS; IMMUNOLOGY; URINARY BLADDER NEOPLASMS;

ANTIGENS, CD47; ENDOSCOPY; HUMANS; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 84908568498     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009457     Document Type: Article

References (39)

1. G. M. Van Dam, G. Themelis, L. M. Crane, N. J. Harlaar, R. G. Pleijhuis, W. Kelder, A. Sarantopoulos, J. S. De Jong, H. J. Arts, A. G. Van Der Zee, J. Bart, P. S. Low, V. Ntziachristos, Intraoperative tumorspecific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat. Med. 17, 1315-1319 (2011).
2. Q. T. Nguyen, R. Y. Tsien, Fluorescence-guided surgery with live molecular navigation-A new cutting edge. Nat. Rev. Cancer 13, 653-662 (2013).
3. R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
4. S. Aldousari, W. Kassouf, Update on the management of non-muscle invasive bladder cancer. Can. Urol. Assoc. J. 4, 56-64 (2010).
5. R. J. Sylvester, A. P. Van Der Meijden, W. Oosterlinck, J. A. Witjes, C. Bouffioux, L. Denis, D. W. Newling, K. Kurth, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466-475; discussion 475-477 (2006).
6. Z. Kirkali, T. Chan, M. Manoharan, F. Algaba, C. Busch, L. Cheng, L. Kiemeney, M. Kriegmair, R. Montironi, W. M. Murphy, I. A. Sesterhenn, M. Tachibana, J. Weider, Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 66, 4-34 (2005).
7. T. R. Griffiths; Action on Bladder Cancer, Current perspectives in bladder cancer management. Int. J. Clin. Pract. 67, 435-448 (2013).
8. J. J. Liu, M. J. Droller, J. C. Liao, New optical imaging technologies for bladder cancer: Considerations and perspectives. J. Urol. 188, 361-368 (2012).
9. A. Stenzl, M. Burger, Y. Fradet, L. A. Mynderse, M. S. Soloway, J. A. Witjes, M. Kriegmair, A. Karl, Y. Shen, H. B. Grossman, Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J. Urol. 184, 1907-1913 (2010).
10. G. A. Sonn, K. E. Mach, K. Jensen, P. L. Hsiung, S. N. Jones, C. H. Contag, T. D. Wang, J. C. Liao, Fibered confocal microscopy of bladder tumors: An ex vivo study. J. Endourol. 23, 197-201 (2009).
11. G. A. Sonn, S. N. Jones, T. V. Tarin, C. B. Du, K. E. Mach, K. C. Jensen, J. C. Liao, Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J. Urol. 182, 1299-1305 (2009).
12. K. Wu, J. J. Liu, W. Adams, G. A. Sonn, K. E. Mach, Y. Pan, A. H. Beck, K. C. Jensen, J. C. Liao, Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology 78, 225-231 (2011).
13. S. B. Willingham, J. P. Volkmer, A. J. Gentles, D. Sahoo, P. Dalerba, S. S. Mitra, J. Wang, H. Contreras-Trujillo, R. Martin, J. D. Cohen, P. Lovelace, F. A. Scheeren, M. P. Chao, K. Weiskopf, C. Tang, A. K. Volkmer, T. J. Naik, T. A. Storm, A. R. Mosley, B. Edris, S. M. Schmid, C. K. Sun, M. S. Chua, O. Murillo, P. Rajendran, A. C. Cha, R. K. Chin, D. Kim, M. Adorno, T. Raveh, D. Tseng, S. Jaiswal, P. Ø. Enger, G. K. Steinberg, G. Li, S. K. So, R. Majeti, G. R. Harsh, M. Van De Rijn, N. N. Teng, J. B. Sunwoo, A. A. Alizadeh, M. F. Clarke, I. L. Weissman, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U. S. A. 109, 6662-6667 (2012).
14. K. S. Chan, I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, H. Gill, J. Presti Jr., H. Y. Chang, M. Van De Rijn, L. Shortliffe, I. L. Weissman, Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U. S. A. 106, 14016-14021 (2009).
15. D. Sahoo, D. L. Dill, R. Tibshirani, S. K. Plevritis, Extracting binary signals from microarray time-course data. Nucleic Acids Res. 35, 3705-3712 (2007).
16. M. Sanchez-Carbayo, N. D. Socci, J. Lozano, F. Saint, C. Cordon-Cardo, Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24, 778-789 (2006).
17. D. Sahoo, D. L. Dill, A. J. Gentles, R. Tibshirani, S. K. Plevritis, Boolean implication networks derived from large scale, whole genome microarray datasets. Genome Biol. 9, R157 (2008).
18. M. Castillo-Martin, J. Domingo-Domenech, O. Karni-Schmidt, T. Matos, C. Cordon-Cardo, Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol. 28, 401-408 (2010).
19. S. Brandau, H. Suttmann, Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomed. Pharmacother. 61, 299-305 (2007).
20. P. L. Hsiung, J. Hardy, S. Friedland, R. Soetikno, C. B. Du, A. P. Wu, P. Sahbaie, J. M. Crawford, A. W. Lowe, C. H. Contag, T. D. Wang, Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat. Med. 14, 454-458 (2008).
21. M. B. Sturm, B. P. Joshi, S. Lu, C. Piraka, S. Khondee, B. J. Elmunzer, R. S. Kwon, D. G. Beer, H. D. Appelman, D. K. Turgeon, T. D. Wang, Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: First-in-human results. Sci. Transl. Med. 5, 184ra61 (2013).
22. M. B. Amin, Histological variants of urothelial carcinoma: Diagnostic, therapeutic and prognostic implications. Mod. Pathol. 22, S96-S118 (2009).
23. H. B. Grossman, A. Stenzl, Y. Fradet, L. A. Mynderse, M. Kriegmair, J. A. Witjes, M. S. Soloway, A. Karl, M. Burger, Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J. Urol. 188, 58-62 (2012).
24. M. Burger, H. B. Grossman, M. Droller, J. Schmidbauer, G. Hermann, O. Drəgoescu, E. Ray, Y. Fradet, A. Karl, J. P. Burgués, J. A. Witjes, A. Stenzl, P. Jichlinski, D. Jocham, Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64, 846-854 (2013).
25. Stanford University. Phase I trial of Hu5F9-G4. In: ClinicalTrials.gov [Internet] (National Library of Medicine, Bethesda, MD, 2000) [cited 27 August 2014]. Available at http://www.clinicaltrials. gov/ct2/show/NCT02216409?term=sikic&rank=2 NLM Identifier: NCT02216409.
26. K. T. Yong, W. C. Law, R. Hu, L. Ye, L. Liu, M. T. Swihart, P. N. Prasad, Nanotoxicity assessment of quantum dots: From cellular to primate studies. Chem. Soc. Rev. 42, 1236-1250 (2013).
27. M. L. James, S. S. Gambhir, A molecular imaging primer: Modalities, imaging agents, and applications. Physiol. Rev. 92, 897-965 (2012).
28. L. Ye, K. T. Yong, L. Liu, I. Roy, R. Hu, J. Zhu, H. Cai, W. C. Law, J. Liu, K. Wang, J. Liu, Y. Liu, Y. Hu, X. Zhang, M. T. Swihart, P. N. Prasad, A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat. Nanotechnol. 7, 453-458 (2012).
29. E. Philips, O. Penate-Medina, P. B. Zanzonico, R. D. Carvajal, P. Mohan, Y. Ye, J. Humm, M. Gönen, H. Kalaigian, H. Schöder, H. W. Strauss, S. M. Larson, U. Wiesner, M. S. Bradbury, Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6, 260ra149 (2014).
30. Memorial Sloan-Kettering Cancer Center. Targeted silica nanoparticles for image-guided intraoperative sentinel lymph node mapping in head and neck melanoma, prostate and cervical/uterine cancer patients. In: ClinicalTrials.gov [Internet] (National Library of Medicine, Bethesda, MD, 2000) [cited 27 August 2014]. Available at http://www.clinicaltrials.gov/ct2/show/NCT02106598?term=NCT02106598&rank=1 NLM Identifier: NCT02106598.
31. University of Alabama. Cetuximab IRDye800 study as an optical imaging agent to detect cancer during surgical procedures. In: ClinicalTrials.gov [Internet] (National Library of Medicine, Bethesda, MD, 2000) [cited 27 August 2014]. Available at https://clinicaltrials.gov/ct2/show/NCT01987375?term=NCT01987375&rank=1NLMIdentifier: NCT01987375.
32. B. Pfost, C. Seidl, M. Autenrieth, D. Saur, F. Bruchertseifer, A. Morgenstern, M. Schwaiger, R. Senekowitsch-Schmidtke, Intravesical α-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J. Nucl. Med. 50, 1700-1708 (2009).
33. J. Carlsson, Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors. Tumour Biol. 33, 653-659 (2012).
34. E. J. Lepin, J. V. Leyton, Y. Zhou, T. Olafsen, F. B. Salazar, K. E. McCabe, S. Hahm, J. D. Marks, R. E. Reiter, A. M. Wu, An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur. J. Nucl. Med. Mol. Imaging 37, 1529-1538 (2010).
35. R. Mazzucchelli, F. Barbisan, A. Santinelli, A. Lopez-Beltran, L. Cheng, M. Scarpelli, R. Montironi, Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. Int. J. Immunopathol. Pharmacol. 22, 755-762 (2009).
36. N. Amara, G. S. Palapattu, M. Schrage, Z. Gu, G. V. Thomas, F. Dorey, J. Said, R. E. Reiter, Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 61, 4660-4665 (2001).
37. S. Rebouissou, I. Bernard-Pierrot, A. De Reyniès, M. L. Lepage, C. Krucker, E. Chapeaublanc, A. Hérault, A. Kamoun, A. Caillault, E. Letouzé, N. Elarouci, Y. Neuzillet, Y. Denoux, V. Molinié, D. Vordos, A. Laplanche, P. Maillé, P. Soyeux, K. Ofualuka, F. Reyal, A. Biton, M. Sibony, X. Paoletti, J. Southgate, S. Benhamou, T. Lebret, Y. Allory, F. Radvanyi, EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med. 6, 244ra91 (2014).
38. D. S. Naik, S. Sharma, A. Ray, S. Hedau, Epidermal growth factor receptor expression in urinary bladder cancer. Indian J. Urol. 27, 208-214 (2011).
39. N. H. Chow, S. H. Chan, T. S. Tzai, C. L. Ho, H. S. Liu, Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7, 1957-1962 (2001).